IRX-2
- Generic Name
- IRX-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 951209-71-5
- Unique Ingredient Identifier
- ZDR4QSJ43F
- Background
IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 11
- Registration Number
- NCT03267680
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath